AstraZeneca (LON:AZN) Receives "Overweight" Rating from JPMorgan Chase & Co.

Key Points

• AstraZeneca's stock has been given an "overweight" rating by JPMorgan Chase & Co., indicating a positive outlook for the company's shares.
• Other analysts have also shown confidence in AstraZeneca, with Shore Capital assigning a "buy" rating and a target price of £145, while Deutsche Bank set a price objective of £110.
• The company's stock performance shows a current price of £126.22, with significant fluctuations over the year, including a low of £9,573.51 and a high of £129.72.

AstraZeneca (LON:AZN - Get Free Report)'s stock had its "overweight" rating restated by investment analysts at JPMorgan Chase & Co. in a research note issued to investors on Monday, Marketbeat Ratings reports.

Other equities research analysts have also issued research reports about the company. Shore Capital reiterated a "buy" rating and issued a £145 target price on shares of AstraZeneca in a research report on Tuesday, October 7th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a £110 price objective on shares of AstraZeneca in a research note on Wednesday, July 30th. Finally, Berenberg Bank restated a "buy" rating and set a £142 target price on shares of AstraZeneca in a research report on Monday, September 1st. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of £134.25.

AstraZeneca Stock Performance

Shares of AZN stock opened at £126.22 on Monday. The business has a fifty day moving average of £117.48 and a 200 day moving average of £109.42. AstraZeneca has a 1 year low of GBX 9,573.51 and a 1 year high of £129.72. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The firm has a market capitalization of £195.67 billion, a price-to-earnings ratio of 2,377.02, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17.

Insider Activity

In other news, insider Aradhana Sarin sold 9,563 shares of the business's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of £115.12, for a total value of £1,100,892.56. Company insiders own 0.14% of the company's stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.